144
Participants
Start Date
October 14, 2024
Primary Completion Date
October 31, 2025
Study Completion Date
February 28, 2026
Injectable extended-release buprenorphine
Participants randomized to the XR-BUP condition will receive XR-BUP study medication for approximately 14 weeks following randomization, including an initial \~2-week period of induction/stabilization.
Sublingual buprenorphine-naloxone
Participants randomized to the SL-BUP condition will receive SL-BUP study medication for approximately 14 weeks following randomization, including an initial \~2-week period of induction/stabilization.
NOT_YET_RECRUITING
New Beginnings Recovery Clinic & Behavioral Health Center, New Martinsville
RECRUITING
Gibson Area Hospital and Health Services - Gibson Recovery Optimizing Wellness, Gibson City
RECRUITING
AppleGate Recovery El Dorado, El Dorado
RECRUITING
Southern Humboldt Community Healthcare District - Jerold Phelps Community Hospital, Garberville
RECRUITING
Oregon Health & Science University Primary Care Clinic, Scappoose, Scappoose
RECRUITING
Providence Northeast Washington Medical Group, Colville
RECRUITING
Penobscot Community Health Care Inc. - Seaport Community Health Center, Belfast
Collaborators (1)
National Institute on Drug Abuse (NIDA)
NIH
National Institutes of Health (NIH)
NIH
The Emmes Company, LLC
INDUSTRY
University of California, Los Angeles
OTHER
RAND
OTHER
Cornell University
OTHER
Oregon Health and Science University
OTHER
University of Illinois at Chicago
OTHER
University of Washington
OTHER
West Virginia University
OTHER
Yih-Ing Hser
OTHER